SCHEMBL4889925

SCHEMBL4889925

CN1CCC(N(C)CC(O)C(O)(c2ccccc2)C2CCCC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
CHRM3 P20309 7/20 0.44
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
CYP2D6 P10635 3/20 0.40
CHRM2 P08172 3/20 0.40
CHRM1 P11229 3/20 0.40
KCNH2 Q12809 2/20 0.40
CHRM4 P08173 2/20 0.40
CHRM5 P08912 2/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
HRH1 P35367 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889924 0.84 KDM4E (0.58) KDM4ECHRM3ATML3MBTL1ALDH1A1
SCHEMBL4889726 0.81 ALDH1A1 (0.49) CHRM3ALDH1A1TSHRKMT2AMEN1
SCHEMBL4889264 0.78 TSHR (0.53) CHRM3ATML3MBTL1ALDH1A1TSHR
SCHEMBL4888039 0.78 CHRM3 (0.59) KDM4ECHRM3ALDH1A1TSHRCYP2D6
SCHEMBL4887153 0.75 CHRM3 (0.50) CHRM3ATML3MBTL1ALDH1A1TSHR
SCHEMBL4882984 0.75 CHRM3 (0.40) CHRM3KMT2AMEN1CHRM2CHRM1
SCHEMBL4883043 0.74 CHRM3 (0.53) KDM4ECHRM3ALDH1A1KMT2ACHRM2
SCHEMBL4888621 0.73 CYP2D6 (0.36) CHRM3ATML3MBTL1ALDH1A1TSHR
SCHEMBL4889873 0.72 MEN1 (0.56) CHRM3TSHRKMT2AMEN1CYP2D6
SCHEMBL4890266 0.71 MEN1 (0.58) KDM4ECHRM3ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US claimed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP claimed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO claimed
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US disclosed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP disclosed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280883-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 KDM4E 3801/4885CHRM3 1/4885ATM 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.